Lists of the top 30 paclitaxel treatment sensitivity pathway markers obtained for the estrogen receptor negative (ERN) HER2-positive (HER2P) and ERN HER2-negative (HER2N) breast cancer types are given in Fig. 3. This evidence concerns the gene ESR1 and breast carcinoma.